The future clinical implications of trained immunity

• Published in: Expert review of clinical immunology Vol. 18; no. 11; pp. 1125 - 1134
• Main Authors: Nica, Valentin, Popp, Radu A., Crișan, Tania O., Joosten, Leo A. B.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02.11.2022
• Subjects: Atherosclerosis; Autoimmune Diseases - therapy; cancer; Humans; Immunity, Innate; Immunologic Memory; inflammation; Ligands; Monocytes; Neoplasms; trained immunity; transplantation; vaccination; cancer; trained immunity; inflammation; Atherosclerosis; transplantation; vaccination
• ISSN: 1744-666X; 1744-8409
• DOI: 10.1080/1744666X.2022.2120470

Trained Immunity (TI) refers to the long-term modulation of the innate immune response, based on previous interactions with microbes, microbial ligands, or endogenous substances. Through metabolic and epigenetic reprogramming, monocytes, macrophages, and neutrophils develop an enhanced capacity to mount innate immune responses to subsequent stimuli and this is persistent due to alterations at the myeloid progenitor compartment. The purpose of this article is to review the current understanding of the TI process and to discuss its potential clinical implications in the near future. We address the evidence of TI involvement in various diseases, the currently developed new therapy, and discuss how TI may lead to new clinical tools to improve existing standards of care. The state of the art in this domain has made considerable progress, linking TI-related mechanisms in multiple immune-mediated pathologies, starting with infections to autoimmune disorders and cancers. As a relatively new area of immunology, it has seen fast progress with many of its applications ready to be investigated in clinical settings.